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io the Editor: An estimated 80% of congenital heart defects result
rom an interaction between susceptibilities in parental and fetal
enomes and environmental exposures including maternal lifestyle
actors (1). We and others have recently reported that women who
ave congenital heart defect-affected pregnancies have alterations
n folate metabolism (2). This population-based case-control study
as undertaken to determine whether these alterations are associ-
ted with specific cardiac phenotypes in their children. The study
opulation, eligibility criteria, and methods have been previously
ublished (2).
Case women had delivered a live-born infant with a non-
yndromic septal, conotruncal, or right- or left-sided obstruc-
ive defect confirmed by echocardiogram, or surgical or autopsy
eport reviewed by a pediatric cardiologist. Cases were classified
nto five defect categories based on anatomical lesion: 1) conotrun-
al—including transposition of the great arteries, tetralogy of Fallot,
runcus arteriosus, double outlet right ventricle, malaligned ventricular
eptal defect, and interrupted aortic arch type B; 2) septal—including
trial, ventricular, and atrioventricular septal defects; 3) right-sided
bstructive—including pulmonary valve stenosis, and pulmonary and
ricuspid atresia; 4) left-sided obstructive—including aortic valve
tenosis, hypoplastic left heart syndrome and variants, coarctation, and
nterrupted aortic arch types A and C lesions; and 5) complex
ases—combination of three or more of the above cardiac defects.
Table 1. Summary Statistics for Plasma Bioma
p Values
Mean (SD) (Int
Homocysteine (mol/l)
Control patients 7.5 (1.7)
Total cases 9.4 (2.4)
Conotruncal 9.5 (2.6)
Septal 9.1 (2.3)
Right obstructive 9.7 (2.4)
Left obstructive 9.6 (2.4)
Complex 9.3 (2.4)
Methionine (mol/l)
Control patients 26.2 (5.0) 2
Total cases 23.8 (5.7) 2
Conotruncal 24.8 (7.3) 2
Septal 23.5 (5.2) 2
Right obstructive 23.0 (5.5) 2
Left obstructive 23.9 (5.5) 2
Complex 25.6 (6.2) 2
Folate (nmol/l)
Control patients 26.8 (13.2) 2
Total cases 23.3 (9.5) 2
Conotruncal 25.2 (9.8) 2
Septal 24.0 (9.9) 2
Right obstructive 19.0 (7.1) 1
Left obstructive 23.8 (9.3) 2
Complex 25.5 (9.5) 2
*Two-sample t test using log-transformed data. †p Value a
multivitamin status, daily caffeine intake, lactation status, th
energy-adjusted dietary folate intake.
SD  standard deviation.Control women had delivered infants unaffected by any birth
efects. Cases and control patients had completed participation in
he National Birth Defects Prevention Study, an ongoing multi-
ite case-control study investigating the etiology of non-syndromic
ongenital malformations, including congenital heart defects (3).
During home visits, a nurse obtained written informed consent
nd a fasting blood sample by routine venipuncture. Plasma
iomarker concentrations of homocysteine, methionine, and folate
ere measured as described elsewhere (2). Case and control
omen were excluded if pregnant, if taking any known folate-
ntagonist medications, or if the pregnancy had ended 6 weeks
rom venipuncture.
Information about the current use of multivitamins, cigarettes,
lcohol, dietary and caffeine intake, and lactation status was
btained during home visits. Daily energy and dietary micronutri-
nt intake, including methionine, folate, vitamin B6, and vitamin
12 were estimated using a food-frequency questionnaire (4). The
rotocol and provisions for informed consent were reviewed and
pproved by the Institutional Review Board at the University of
rkansas for Medical Sciences.
Plasma biomarker data were log-transformed before analysis.
ase and control biomarker concentrations were compared using a
tudent t test. Linear regression was used to adjust these compar-
sons for covariates. Adjusted odds ratios (OR) and corresponding
Concentrations and Crude and Adjusted
edian
rtile Range) p Value* Adjusted Value†
.4, 8.6)
.7, 10.8) 0.0001 0.0001
.4, 11.3) 0.0001 0.0001
.6, 10.5) 0.0001 0.0001
.0, 11.0) 0.0001 0.0001
.2, 10.8) 0.0001 0.0001
.3, 11.0) 0.0001 0.0001
2.2, 29.2)
9.6, 27.1) 0.0001 0.0001
9.1, 28.1) 0.1446 0.1568
9.5, 26.4) 0.0001 0.0001
9.3, 25.6) 0.0001 0.0006
9.5, 27.8) 0.0053 0.0120
1.7, 27.2) 0.9738 0.7107
7.7, 30.0)
6.8, 28.6) 0.0054 0.0173
6.0, 30.6) 0.6006 0.4423
7.6, 28.2) 0.0953 0.3337
4.0, 22.2) 0.0001 0.0019
7.8, 30.2) 0.2007 0.3103
9.7, 32.5) 0.7546 0.1133
for the mother’s age, race, education, smoking, drinking,
val between the end of pregnancy and interview, and dailyrker
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February 7, 2006:683–915% confidence intervals (CI) for the association between plasma
iomarkers and cardiac phenotypes status were computed using
ogistic regression. For each biomarker, quartile cut-points were
omputed based on the distribution of biomarkers among control
atients. Data analyses were performed using the SAS statistical
ackage (version 9.1, SAS Institute, Cary, North Carolina).
A total of 285 congenital heart defect cases and 157 control
atients had plasma biomarkers measured. The participation rate
as 91.5% for cases and 78.0% for control patients. The most
revalent congenital heart defect phenotype was septal heart
efects (43.9%), followed by right-sided obstructive defects
19.3%), and left-sided obstructive defects (14.0%). Only 35
12.3%) of the case children had conotruncal defects. There were
0 (10.5%) cases that had three or more of the above cardiac
efects (complex).
The sample consisted primarily of Caucasian women; 63% of
he cases were younger than age 30 years; and 40% reported
egular multivitamin use. Nearly 48% of cases consumed alcohol.
moking was more prevalent among cases than control patients
28.8% vs. 15.3% respectively, p  0.0016). There were no
ignificant differences between cases and control patients in median
ietary and total micronutrient intake from diet plus supplements,
ncluding methionine, folate, vitamin B6, and vitamin B12.
Plasma concentrations for homocysteine, methionine, and folate
re summarized in Table 1. After controlling for covariates,
ncluding maternal age, race, education, smoking, multivitamin
upplement intake, alcohol consumption, lactation status, caffeine
ntake, energy-adjusted dietary folate intake, and the interval
etween the end of pregnancy and venipuncture, plasma homo-
ysteine levels were significantly elevated in all phenotypes com-
ared with control patients. Women who had children with septal,
ight-sided, and left-sided obstructive lesions had significantly
ower methionine than control patients. Folate levels in women
ho had pregnancies affected by right-sided obstructive lesions
ere significantly lower than control patients.
Table 2 shows adjusted odds ratios for the association between
ach biomarker and selected cardiac phenotypes. Among women
ho had homocysteine concentrations in the highest quartile, the
dds of being a case were significantly greater than the odds of
eing a control. The ORs ranged from 3.69 (95% CI 2.10 to 6.49)
or women with children with septal defects to 9.11 (95% CI 3.24
o 25.60) for those with a child with conotruncal defects. For those
n the lowest quartile of methionine, the highest OR was observed
or women who had a child affected by a left-sided obstructive
esion (OR 3.42; 95% CI 1.55 to 7.55). For women in the lowest
uartile of plasma folate distribution, all odds ratios had corre-
able 2. The Association Between Maternal Biomarkers and Car
Biomarkers
(Percentile, Cut-Point*)
Cases Conotruncal Defec
n (%)
OR (95% CI)†
n (%)
OR (95% CI)†
omocysteine 160 (56.1) 21 (60.0)
(75th, 8.59 mol/l) 5.22 (3.21, 8.49) 9.11 (3.24, 25.60)
ethionine 135 (47.5) 15 (42.9)
(25th, 22.18 mol/l) 2.55 (1.61, 4.02) 2.32 (0.94, 5.73)
olate 82 (28.8) 9 (25.7)
(25th, 17.74 nmol/l) 1.23 (0.75, 2.01) 1.16 (0.41, 3.25)
Cut-points and percentiles based on each biomarker concentration distribution within
CI  confidence interval; OR  odds ratio.ponding 95% CIs that included one. SOur findings indicate that women who had children with
ongenital heart defects had higher plasma homocysteine concen-
rations than women without such a history. Among most con-
enital heart defects, folate intake from diet and supplements was
imilar between cases and control patients, as was mean plasma
olate concentration. Following mandatory food fortification with
olic acid, homocysteine may be a more salient marker of increased
isk than folate intake or plasma folate concentrations. The mean
lasma methionine concentrations were significantly different from
ontrol patients among women who had children affected by septal
nd obstructive defects, but not among those who had children
ith conotruncal or complex defects.
Important methodologic limitations of our study should be
onsidered. Our intent was to compare plasma biomarker concen-
rations in women who had a specific congenital heart defect-
ffected pregnancy compared with control women. Because of
imitations in sample sizes for some congenital heart defect
henotypes, we had limited statistical power to detect a difference
n plasma biomarker concentration distributions across cardiac
henotypes. Cases had higher participation rates than control
atients, and thus factors that determined participation rates may
e differentially distributed between cases and control patients.
lthough plasma biomarkers were not measured at organogenesis,
ur findings support the hypothesis that imbalances in homocys-
eine metabolism exist in women with congenital heart defect-
ffected pregnancies.
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Phenotype Status
Septal Defects
Right-Sided
Obstructive Defects
Left-Sided
Obstructive Defects
n (%)
OR (95% CI)†
n (%)
OR (95% CI)†
n (%)
OR (95% CI)†
66 (52.8) 34 (61.8) 23 (57.5)
3.69 (2.10, 6.49) 5.46 (2.54, 11.74) 8.37 (3.34, 20.99)
59 (47.2) 30 (54.5) 20 (50.0)
2.48 (1.44, 4.27) 3.18 (1.55, 6.50) 3.42 (1.55, 7.55)
32 (25.6) 25 (45.5) 10 (25.0)
0.92 (0.50, 1.70) 1.80 (0.87, 3.73) 0.89 (0.36, 2.21)
ols subjects. †ORs and 95% CI adjusted for covariates listed in the previous footnote.diac
tsettlement Proceeds Act of 2000. The contents are solely the responsibility of the authors
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Relationship Between Patient’s Risk Profile and Benefits in Mortality From Adjunctive
Abciximab to Mechanical Revascularization for ST-Segment Elevation Myocardial Infarction:s of Randomized Trialso the Editor: Adjunctive abciximab has been shown to reduce
ortality in patients undergoing mechanical revascularization for
T-segment elevation myocardial infarction (STEMI) (1). The
oal of this study was to investigate, by the use of a meta-
egression analysis of randomized trials, whether the benefits in
ong-term mortality from abciximab administration correlated
ith the patient’s risk profile.
The literature was scanned by formal searches of electronic
atabases (MEDLINE, PubMed) and the scientific session ab-
tracts in Circulation, the Journal of American College of Cardiology,
nd the European Heart Journal from January 1990 to December
004. The following key words were used: randomized trial,
yocardial infarction, reperfusion, primary angioplasty, facilitated
ngioplasty, stenting, glycoprotein IIb/IIIa inhibitors, abciximab.
ll data were extracted by two investigators. Data were managed
ccording to the intention-to-treat principle.
The end point was mortality at 6 to 12 months of follow-up.
tatistical analysis was performed using the Review Manager 4.27
reeware package (Cochrane Collaboration, Oxford, United King-
om), the SPSS 11.5 statistical package (SPSS Inc., Chicago,
llinois), and SAS version 8.2 (SAS Institute Inc., Cary, North
arolina). Odds ratio (OR) and 95% confidence intervals (CIs)
ere used as summary statistics (1).
A fixed-effect meta-regression analysis for the log-odds ratio on
ortality (expressed as odds) of the control group was carried out
y resorting to the Proc MIXED procedure of SAS version 8.2
SAS Institute Inc.) according to the approach proposed by van
able 1. Characteristics of Randomized Trials Included in the M
Study Period n Study-Drug D
APPORT (1) 1995–1997 483 Abciximab* (n  241
DMIRAL (2) 1997–1998 300 Stenting  abciximab
ADILLAC (3) 1997–1999 2,082 Abciximab*  stent (
control  stent (n
SAR-2 (4) 1997–1998 401 Stenting (n  200) v
etronio et al. (5) 1998–2000 89 Abciximab* (n  44)
orman et al. (6) 1998–2001 163 Early (n  56) vs. lat
Abciximab* vs. placeb
CE (7) 2001–2002 400 Stenting (n  200) vouwelingen et al. (2). Results are reported as regression coeffi-
ients with associated 95% CI and two-sided p values. The
stimated meta-regression line was plotted in graph together with
he observed log-odds ratios.
A total of seven randomized trials with available follow-up data
ere analyzed (Table 1), involving 3,918 patients (1,999 in the
bciximab group and 1,919 in the placebo group). In almost all
rials, abciximab was started after initial angiography. Abciximab
as associated with a significant reduction in 6- to 12-month
ortality (4.4% vs. 6.2%, OR [95% CI]  0.69 [0.52 to 0.92],
 0.01, p heterogeneity 0.15). Figure 1 shows the relationship
etween the patient’s risk profile and the benefits from abciximab
dministration in terms of 6- to 12-month mortality (b  9.9
20.1 to 0.21], p  0.053).
The main finding of this meta-analysis is that the mortality
enefits of adjunctive abciximab therapy to mechanical revascular-
zation for ST-segment elevation myocardial infarction are related
o the patient’s risk profile.
The benefits in mortality may be the effects of abciximab in
educing distal embolization and improving myocardial perfusion,
actors known to be determinants of long-term survival (3).
It should be remarked that highly selected non-high-risk
atients are commonly enrolled in randomized trials, whereas
enefits in mortality have been shown mostly in trials enrolling
igh-risk patients. In fact, by using a meta-regression analysis, a
irect correlation was found between the patient’s risk profile and
he benefits from abciximab administration in terms of long-term
nalysis
Long-Term Mortality
(%)
(Number of Patients) Abciximab Control p Value
lacebo (n  242) 4.1 4.5 0.83
151) vs. placebo (n  149) 3.4 7.3 0.13
24) or balloon (n  528),
2) or balloon (n  518)
4.2 4.4 0.83
iximab*  stenting (n  201) 6.0 8.5 0.33
lacebo (n  45) 4.5 13.3 0.15
stangiography; n  56)
 51)
4.5 13.7 0.036
iximab*  stenting (n  200) 5.0 10.5 0.04eta-A
esign
) vs. p
* (n 
n  5
 51
s. abc
vs. p
e (po
o (n
s. abcN Engl J Med 2001;344:1895–903. (3) N Engl J Med 2002;346:957–66. (4) J Am
0:533–6. (7) Circulation 2004;109:1704–6.
